IDiyas

For the Inventor, By the Inventor

Beijing, China

Yunhang Guo

USPTO Granted Patents = 23 

 

Average Co-Inventor Count = 3.2

ph-index = 7

Forward Citations = 153(Granted Patents)


Company Filing History:

goldMedal12 out of 52 
 
Beigene, Ltd.
 patents
silverMedal11 out of 22 
 
Beigene Switzerland Gmbh
 patents

Years Active: 2016-2025

where 'Filed Patents' based on already Granted Patents

23 patents (USPTO):
1. 12286430 - Bcl-2 inhibitor (2025-04-29),
2. 12103931 - Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof (2024-10-01),
3. 12077536 - BCL-2 inhibitors (2024-09-03),
4. 11999743 - Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof (2024-06-04),
5. 11970500 - Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)- 2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof (2024-04-30),
6. 11884674 - Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof (2024-01-30),
7. 11851437 - Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof (2023-12-26),
8. 11814389 - Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof (2023-11-14),
9. 11701357 - Treatment of B cell cancers using a combination comprising Btk inhibitors (2023-07-18),
10. 11591340 - Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof (2023-02-28),
11. 11555038 - Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof (2023-01-17),
12. 11472788 - Benzoimidazoles as selective inhibitors of indoleamine 2,3-dioxygenases (2022-10-18),
13. 11420968 - Bcl-2 inhibitors (2022-08-23),
14. 11377449 - BTK inhibitors with improved dual selectivity (2022-07-05),
15. 11142528 - Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators (2021-10-12),

Title: Innovations and Contributions of Yunhang Guo in Biopharmaceuticals

Introduction

Yunhang Guo, based in Beijing, China, is a prominent inventor in the field of biopharmaceuticals. With a significant portfolio of 23 patents, he has made substantial contributions to the development of therapeutic compounds aimed at treating various diseases. His innovative work focuses primarily on mechanisms of apoptosis and related pathways, which are crucial in cancer and other dysregulated conditions.

Latest Patents

Among Yunhang Guo's notable advancements is a Bcl-2 inhibitor, which is designed to impede both wild type and mutated versions of the Bcl-2 protein, specifically targeting Bcl-2 mutations G101V and D103Y. This compound offers potential therapeutic avenues for dysregulated apoptotic diseases. Additionally, he has developed a crystalline form of a compound known as (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide. This invention not only details the preparation methods but also highlights its uses in formulating medicinal products aimed at treating various diseases.

Career Highlights

Yunhang Guo has held positions at notable institutions such as BeiGene, Ltd. and BeiGene Switzerland GmbH. His career in these organizations has allowed him to be at the forefront of biopharmaceutical innovation, significantly influencing drug development strategies and contributing to scientific research practices.

Collaborations

Throughout his career, Yunhang Guo has collaborated with distinguished professionals, including Zhiwei Wang and Gongyin Shi. These partnerships have often fostered an environment of creativity and innovation, driving forward the development of new therapeutic solutions in the highly competitive pharmaceutical landscape.

Conclusion

Yunhang Guo's work and inventive prowess not only underscore his significance in the pharmaceutical sector but also reflect the broader impact of innovation within the medical field. His contributions, particularly in the realm of apoptotic regulation, highlight the critical role inventors play in transforming scientific research into actionable therapeutic solutions. As he continues to push the boundaries of biopharmaceutical developments, Guo remains an influential figure to watch in the industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…